April 26, 2026 FDA Grants Priority Review Vouchers for Psychedelic Drugs to Treat Depression and PTSD Under Trump Administration Plan
April 26, 2026 The Drug Story Behind Every Medicine: From Ambien to Wegovy – First Opinion Podcast Transcript with Thomas Goetz
April 23, 2026 Trump Announces Drug Pricing Deal With Regeneron, Including Medicaid Price Cuts, $225 Praluent and $27B U.S. Investment
April 22, 2026 Title: Roche’s Fenebrutinib Shows Promise in MS Trials — But Safety Concerns Loom Ahead of FDA Review
April 13, 2026 New Molecules Offer Breakthrough Treatment for Lupus and Arthritis Without Weakening Immunity
